37785-47-0

Basic information

• Product Name: 2-(4-hydroxy-3-phenoxyphenyl)propanoic acid
• CAS NO: 37785-47-0
• Molecular Formula: C₁₅H₁₄O₄
• Molecular Weight: 258.2693
• Mol File: 37785-47-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 401.7°C at 760 mmHg
• Flash Point: 149.4°C
• Density: 1.271g/cm³
• Vapor Pressure: 3.56E-07mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: 2-(4-hydroxy-3-phenoxyphenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-hydroxy-3-phenoxyphenyl)propanoic acid(37785-47-0)
• EPA Substance Registry System: 2-(4-hydroxy-3-phenoxyphenyl)propanoic acid(37785-47-0)

Safety Data

• Hazardous Substances Data: 37785-47-0(Hazardous Substances Data)

Usage

Classification

Nonsteroidal anti-inflammatory drug (NSAID).

Function

Relieves pain and reduces inflammation in conditions such as arthritis.

Mechanism of action

Inhibits the production of prostaglandins, which are chemicals in the body that cause pain and inflammation.

Common uses

Treating pain, swelling, and stiffness caused by conditions such as arthritis, gout, and muscle injuries.

Form

Available in oral form as a tablet or capsule.

Prescription

Should be taken exactly as directed by a doctor.

Side effects

May cause stomach irritation or bleeding, among other potential side effects.

Upstream product

• 29679-58-1 Fenoprofen 

Relevant articles and documents

Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans

The concentrations of the (R)- and (S)-enantiomers of fenoprofen (α-methyl-3-phenoxy-benzeneacetic acid) were measured in plasma and urine of volunteers after oral administration of the (R,S)-racemate. In addition, urinary concentrations of the (R)- and (S)-4'-hydroxy metabolite of fenoprofen, the major metabolite, were measured. The (R)-enantiomer of fenoprofen was stereoselectively inverted to (S)-fenoprofen, which was the major isomeric form found in plasma and urine. A potency comparison of the enantiomers in vitro showed the (S)-isomer to be 35 times more active than the (R)-isomer in inhibiting the fatty acid cyclo-oxygenase pathway from human platelets. In vivo, the similar pharmacological potency of the two enantiomers previously observed in experimental animals may have been due to the rapid inversion of the (R)- to (S)-isomer.